Business Description
Algernon Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA10639L1013
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.11 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 45 | |||||
3-Year EPS without NRI Growth Rate | 44.7 | |||||
3-Year FCF Growth Rate | 52.3 | |||||
3-Year Book Growth Rate | -63.1 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 67.35 | |||||
9-Day RSI | 58.23 | |||||
14-Day RSI | 53.33 | |||||
6-1 Month Momentum % | 52.94 | |||||
12-1 Month Momentum % | -40.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.03 | |||||
Quick Ratio | 0.03 | |||||
Cash Ratio | 0.02 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -33.7 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -253.08 | |||||
ROA % | -106.7 | |||||
ROIC % | -80.46 | |||||
ROCE % | -177.87 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 6.5 | |||||
EV-to-EBIT | -0.76 | |||||
EV-to-EBITDA | -0.77 | |||||
EV-to-Forward-Revenue | 29.71 | |||||
EV-to-FCF | -1.7 | |||||
Earnings Yield (Greenblatt) % | -131.58 | |||||
FCF Yield % | -57.41 |